Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Gilead signs pact with 7 firms for cheap copies of hepatitis C drug

Gilead's licensing agreement with firms including India's Cipla Ltd and Ranbaxy Laboratories Ltd clears the way for the launch of a cheap generic version of the drug in 91 developing countries that make up 54 percent of the total global hepatitis burden.

Published
15 September 2014
From
Reuters
AbbVie 3D hepatitis C regimen is well-tolerated in Phase 3 trials

AbbVie's 3D hepatitis C regimen containing ABT-450, ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 SAPPHIRE trials, according to a pooled analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC.

Published
15 September 2014
From
HIVandHepatitis.com
Gilead to raise price for new hepatitis C drug above $84000

The fixed-dose regimen version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

Published
15 September 2014
From
Reuters
Simeprevir in hepatitis C: added benefit for certain patients

Added benefit for untreated and relapsed patients with unclear extent; major added benefit for non-responders; missing data for patients with HIV coinfection and genotype 4 patients.

Published
10 September 2014
From
German Institute for Quality and Efficiency in Health Care
Gilead close to sending $84,000 drug to poor countries

Gilead Sciences Inc. is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.

Published
09 September 2014
From
Bloomberg
HIV-Negative Gay Men May Acquire Hepatitis C Sexually

HIV-negative men who have sex with men (MSM) are apparently at risk for sexual acquisition of hepatitis C virus (HCV), the National AIDS Treatment Advocacy Project reports. Their risk factors are likely similar to those of HIV-positive men. Researchers at Chelsea and Westminster Hospital in London conducted a retrospective study of the clinic’s patients in which they identified 44 acute cases of hep C among HIV-negative MSM between January 2010 and December 2013.

Published
09 September 2014
From
Aidsmeds.com
US: HIV medical organizations challenge insurer restrictions to HCV treatment

The American Academy of HIV Medicine (AAHIVM) and the HIV Medicine Association (HIVMA), the two largest professional associations representing HIV clinicians in the U.S., are challenging new health plan cost control policies barring many qualified HIV care providers from prescribing certain medications that treat hepatitis C (HCV).

Published
04 September 2014
From
EATG / AAHIVM / HIVMA
That holiday pedicure may leave you with hepatitis C

"In places like Bali, Thailand, Vietnam and the Philippines, hepatitis C can be nine or 10 times more prevalent than at home, and this coupled with generally lower standards of equipment sterilisation in the average tattoo parlour or where you get pedicures can greatly increase the risk of infection," Tyrell says.

Published
01 September 2014
From
Courier Mail
MSF urges BMS to make daclatasvir accessible in low-and middle-income countries

Welcoming the EMA's approval of daclatasvir on August 27, 2014, the MSF said that the BMS must rapidly register daclatasvir in those countries with a high burden of hepatitis C, especially in those countries with a high prevalence of genotype 3. It also urged BMS to ensure daclatasvir is affordable in those countries with a high burden of hepatitis C.

Published
01 September 2014
From
Pharmabiz
European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

Bristol-Myers Squibb Company today announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults. Daklinza, when used in combination with sofosbuvir (Sovaldi), is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials

Published
27 August 2014
From
Bristol-Myers Squibb

Filter by country